AI Article Synopsis
Article Abstract
A point-of-care blood test for the detection of an emerging biomarker, CCL17/TARC, could prove transformative for the clinical management of classic Hodgkin lymphoma (cHL). Primary care diagnosis is challenging due to nonspecific clinical presentation and lack of a diagnostic test, leading to significant diagnostic delays. Treatment monitoring encounters false-positive and negative results, leading to avoidable chemotherapy toxicity, or undertreatment, impacting patient morbidity and mortality. Here, we present an amperometric CCL17/TARC immunosensor, based on the utilization of a thiolated heterobifunctional cross-linker and sandwich antibody assay, to facilitate novel primary care triage and chemotherapy monitoring strategies for cHL. The immunosensor shows excellent analytical performance for clinical testing; linearity ( = 0.986), detection limit (194 pg/mL), and lower and upper limits of quantitation (387-50 000 pg/mL). The biosensor differentiated all 42 newly diagnosed cHL patients from healthy volunteers, based on serum CCL17/TARC concentration, using blood samples collected prior to treatment intervention. The immunosensor also discriminated between paired blood samples of all seven cHL patients, respectively, collected prior to treatment and during chemotherapy, attributed to the decrease in serum CCL17/TARC concentration following chemotherapy response. Overall, we have shown, for the first time, the potential of an electrochemical CCL17/TARC biosensor for primary care triage and chemotherapy monitoring for cHL, which would have positive clinical and psychosocial implications for patients, while streamlining current healthcare pathways.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acssensors.1c00972 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MASLD Is Associated With an Increased Long-Term Risk of Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis.
Liver Int
January 2025
Department of Medicine, University of Verona, Verona, Italy.
Background: Studies have reported an association between metabolic dysfunction-associated steatotic liver disease (MASLD) and an increased risk of developing atrial fibrillation (AF). However, the magnitude of the risk and whether this risk varies with the severity of MASLD remains uncertain.
Methods: In this systematic review and meta-analysis, we searched three large electronic databases using predefined keywords to identify cohort studies (published up to 30 September 2024) in which MASLD was diagnosed by liver biopsy, imaging methods, International Classification of Diseases (ICD) codes, or blood-based scores.
MedVantage: A Primary Care Model for Populations With High Social and Medical Needs.
Ochsner J
January 2024
The University of Queensland Medical School, Ochsner Clinical School, New Orleans, LA.
Despite the substantial expenditures on health care in the United States, persistent underperformance in health system metrics necessitates innovative approaches to address complex patient needs. The MedVantage Clinic in New Orleans, Louisiana, offers a regionally tailored, value-based primary care model targeting patients with high social and medical needs. This study provides an evaluation of the efficacy of the MedVantage Clinic in improving the cost of care and service utilization for this population.
View Article and Find Full Text PDFThe role of parental child marriage in children's food security and nutritional status: a prospective cohort study in Indonesia.
Front Public Health
December 2024
Department of Public Health and Primary Care/Health Campus The Hague, Leiden University Medical Center, Leiden, Netherlands.
Objectives: Assessing children's food and nutrition security in Indonesia, especially among children from parents who experienced child marriage, is crucial for policymakers. This study investigates the role of parental child marriage in children's food security and nutritional status.
Methods: We analyze data from Indonesia Family Life Survey (IFLS) wave 4 (2007) and 5 (2014), involving 1,612 households.
Immunoadjuvant therapy in the regulation of cell death in sepsis: recent advances and future directions.
Front Immunol
December 2024
Department of Emergency and Critical Care Medicine, Aichi Medical University, Nagakute, Japan.
Sepsis is characterized by a concomitant early pro-inflammatory response by immune cells to an infection, and an opposing anti-inflammatory response that results in protracted immunosuppression. The primary pathological event in sepsis is widespread programmed cell death, or cellular self-sacrifice, of innate and adaptive immune cells, leading to profound immunological suppression. This severe immune dysfunction hampers effective primary pathogen clearance, thereby increasing the risk of secondary opportunistic infections, latent viral reactivation, multiple organ dysfunction, and elevated mortality.
View Article and Find Full Text PDFIdentification of Potential Drug Targets for the Treatment of Severe Burn Wounds from a Multi-Omics Perspective.
J Inflamm Res
December 2024
Department of Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, People's Republic of China.
Purpose: Severe burns result in significant skin damage, impairing its primary role as an infection barrier and presenting substantial treatment challenges. Despite improvements in the treatment of burn patients due to advancements in materials and techniques, there remains a need for novel therapeutic approaches to enhance burn prognosis further.
Patients And Methods: Several types of genomic methods are used in this study, such as differential gene expression analysis, weighted gene co-expression network analysis (WGCNA), machine learning, and Mendelian randomization (MR), to find genes that are linked to severe burns and create a diagnostic nomogram to see how well these genes can predict severe burns.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!